FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290432004> ?p ?o ?g. }

• W4290432004 endingPage "95" @default.
• W4290432004 startingPage "175" @default.
• W4290432004 abstract "The role of chemotherapy in the management of patients with SCCHN has not been adequately defined. For patients with recurrent or metastatic disease, several single agents can induce significant tumor regression in 20% to 40% of cases and provide palliation for the individual with a symptomatic or life-threatening lesion. However, complete or long-term control of tumor with chemotherapy alone remains poor. In addition, current regimens of combination chemotherapy have not proved superior to single agents in this setting. Thus, the routine use of combination chemotherapy for patients with metastatic or recurrent SCCHN cannot be justified outside an investigational study. New single agents of promise must be sought and more active combinations of chemotherapy devised for the treatment of patients with metastatic or recurrent SCCHN. Strategies for drug development include the investigation of cisplatin analogues, such as iproplatin and carboplatin, the exploitation of potentially synergistic drug schedules, and the administration of chemotherapy by continuous infusion. That the use of continuous-infusion drug delivery can enhance antitumor activity and limit toxicity for patients with recurrent or metastatic SCCHN was convincingly demonstrated by Kish and co-workers132 in a randomized trial of cisplatin with either bolus or continous-infusion 5-fluourouracil. The antitumor activity of combination chemotherapy may also be increased by the use of mid-cycle nonmyelosuppressive agents, such as methotrexate with leucovorin rescue, or the administration of alternating cycles of non-cross-resistant regimens of combination chemotherapy. The optimal use of chemotherapy in the multidisciplinary treatment of patients with previously untreated SCCHN must also be clarified. Uncontrolled studies of induction chemotherapy report increasingly positive results. Several regimens of induction combination chemotherapy are now associated with significant tumor regression in 70% to 90% of patients, and complete clinical regression of tumor in 20% to 50%. Of patients with a complete clinical response to induction chemotherapy, a complete pathologic response has been documented in 30% to 70% of patients who undergo surgical resection after chemotherapy. It is now evident that patients achieving a complete response to induction chemotherapy have a high probability of local-regional control of tumor and cure. Conversely, patients not responding to induction chemotherapy fare poorly regardless of subsequent local treatment, and it may be appropriate to defer excessively morbid surgical procedures in this patient populus.(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
• W4290432004 created "2022-08-07" @default.
• W4290432004 creator A5012462650 @default.
• W4290432004 creator A5082379633 @default.
• W4290432004 creator A5085095126 @default.
• W4290432004 date "1987-01-01" @default.
• W4290432004 modified "2023-09-28" @default.
• W4290432004 title "Induction chemotherapy as initial treatment for advanced head and neck cancer: a model for the multidisciplinary treatment of solid tumors." @default.
• W4290432004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3331380" @default.
• W4290432004 hasPublicationYear "1987" @default.
• W4290432004 type Work @default.
• W4290432004 citedByCount "1" @default.
• W4290432004 crossrefType "journal-article" @default.
• W4290432004 hasAuthorship W4290432004A5012462650 @default.
• W4290432004 hasAuthorship W4290432004A5082379633 @default.
• W4290432004 hasAuthorship W4290432004A5085095126 @default.
• W4290432004 hasConcept C121608353 @default.
• W4290432004 hasConcept C126322002 @default.
• W4290432004 hasConcept C143998085 @default.
• W4290432004 hasConcept C2776530083 @default.
• W4290432004 hasConcept C2776694085 @default.
• W4290432004 hasConcept C2778239845 @default.
• W4290432004 hasConcept C2781059491 @default.
• W4290432004 hasConcept C2781451048 @default.
• W4290432004 hasConcept C3019864225 @default.
• W4290432004 hasConcept C71924100 @default.
• W4290432004 hasConceptScore W4290432004C121608353 @default.
• W4290432004 hasConceptScore W4290432004C126322002 @default.
• W4290432004 hasConceptScore W4290432004C143998085 @default.
• W4290432004 hasConceptScore W4290432004C2776530083 @default.
• W4290432004 hasConceptScore W4290432004C2776694085 @default.
• W4290432004 hasConceptScore W4290432004C2778239845 @default.
• W4290432004 hasConceptScore W4290432004C2781059491 @default.
• W4290432004 hasConceptScore W4290432004C2781451048 @default.
• W4290432004 hasConceptScore W4290432004C3019864225 @default.
• W4290432004 hasConceptScore W4290432004C71924100 @default.
• W4290432004 hasLocation W42904320041 @default.
• W4290432004 hasOpenAccess W4290432004 @default.
• W4290432004 hasPrimaryLocation W42904320041 @default.
• W4290432004 hasRelatedWork W1828385635 @default.
• W4290432004 hasRelatedWork W2007665175 @default.
• W4290432004 hasRelatedWork W2013017791 @default.
• W4290432004 hasRelatedWork W2020319882 @default.
• W4290432004 hasRelatedWork W2034905626 @default.
• W4290432004 hasRelatedWork W2411113428 @default.
• W4290432004 hasRelatedWork W2411515331 @default.
• W4290432004 hasRelatedWork W2419536502 @default.
• W4290432004 hasRelatedWork W3206704704 @default.
• W4290432004 hasRelatedWork W335570002 @default.
• W4290432004 isParatext "false" @default.
• W4290432004 isRetracted "false" @default.
• W4290432004 workType "article" @default.